EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A comprehensive prognostic and immunological implications of PFKP in pan-cancer

Xiaodong Ling, Luquan Zhang, Chengyuan Fang, Hao Liang, Jianqun Ma

Cancer Cell International · 09.09.2024 · 24 (1)

DOI: 10.1186/s12935-024-03497-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell International, online erschienen am 09.09.2024. Verfasst von Xiaodong Ling und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, Heilongjiang, 150040, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Haiyan Foundation of Harbin Medical University Cancer Hospital, Beijing Medical Award Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Phosphofructokinase P (PFKP) is a key rate-limiting enzyme in glycolysis, playing a crucial role in various pathophysiological processes. However, its specific function in tumors remains unclear. This study aims to evaluate the expression and specific role of PFKP across multiple tumor types (Pan-cancer) and to explore its potential clinical significance as a therapeutic target in cancer treatment. METHODS: We analyzed the expression of PFKP, immune cell infiltration, and patient prognosis across various cancers using data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Additionally, we conducted a series of experiments in lung cancer cells, including Western blot, CCK-8 assay, colony formation assay, transwell migration assay, scratch wound healing assay, LDH release assay, and flow cytometry, to evaluate the impact of PFKP on tumor cells. RESULTS: PFKP was found to be highly expressed in most cancers and identified as a prognostic risk factor. Elevated PFKP expression is associated with poorer clinical outcomes, particularly in lung adenocarcinoma (LUAD). Receiver operating characteristic (ROC) curve analysis indicated that PFKP can effectively differentiate between cancerous and normal tissues. The expression of PFKP in most tumors showed significant correlations with tumor mutational burden (TMB), microsatellite instability (MSI), immune score, and immune cell infiltration. In vitro experiments demonstrated that PFKP overexpression promotes lung cancer cell proliferation and migration while inhibiting apoptosis, whereas PFKP deficiency results in the opposite effects. CONCLUSION: PFKP acts as an oncogene involved in tumorigenesis and may influence the immune microenvironment within the tumor. Our findings suggest that PFKP could serve as a potential biomarker for predicting prognosis and the efficacy of immunotherapy in tumors.

Schlagwörter

Stichwörter der Autor:innen

Immune analysisLUADPFKPPan-cancerPrognosis prediction

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, Heilongjiang, 150040, China.
  • Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, Heilongjiang, 150040, China. jianqunma@hrbmu.edu.cn.

Förderung

  • Haiyan Foundation of Harbin Medical University Cancer Hospital
  • Beijing Medical Award Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Ling, X., Zhang, L., Fang, C., Liang, H., & Ma, J. (2024). A comprehensive prognostic and immunological implications of PFKP in pan-cancer. Cancer Cell International, 24(1). https://doi.org/10.1186/s12935-024-03497-w

Vancouver

Ling X, Zhang L, Fang C, Liang H, Ma J. A comprehensive prognostic and immunological implications of PFKP in pan-cancer. Cancer Cell International. 2024;24(1). doi:10.1186/s12935-024-03497-w

BibTeX
@article{Ling2024,
  author = {Ling, Xiaodong and Zhang, Luquan and Fang, Chengyuan and Liang, Hao and Ma, Jianqun},
  title = {A comprehensive prognostic and immunological implications of PFKP in pan-cancer},
  journal = {Cancer Cell International},
  year = {2024},
  volume = {24},
  number = {1},
  doi = {10.1186/s12935-024-03497-w}
}
Kostenlos starten →